PUBLIC COMPANY
save$VERAVera Therapeutics, Inc.
$VERA29.79-1.18%Brisbane, CA, USupdated 9d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Monthly Dosing of Atacicept in IgAN
- phase2Atacicept in Multiple Glomerular Diseases
- phase3Atacicept in Subjects With IgA Nephropathy
- phase3Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
- phase2A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
- phase2A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
🐶 Hiring Signal
News
- AI chatbots aren’t therapists. But can they finally get men to open up?AI chatbots are imperfect therapists. But can they finally get men to talk?stat · 8d ago
- Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked NovemberAlso lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.biospace · 10d ago
- Alethio raises $90M to target rare blood cancersThe startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a group of conditions known as myeloproliferative neoplasms.biopharma_dive · 12d ago
- Merck KGaA makes noise in hematology with $1.1B Silence buySilence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.biospace · 28d ago
- Merck KGaA bets on RNAi with $1.3B Silence buyoutThe acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.biopharma_dive · 28d ago
- Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…biospace · 29d ago
- Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…biospace · 29d ago
- Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer winGermany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo.fiercebiotech · 29d ago
- Roche, Ionis RNA drug scores in kidney disease studyThe results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.biopharma_dive · 1mo ago
- Roche kidney drug's Phase 3 win sets up path to accelerated approvalRoche moves closer to entering an increasingly crowded kidney disease market where Novartis, Calliditas, Travere, Otsuka and Vera already have approved drugs. The Swiss pharma reported interim Phas…endpoints · 1mo ago
Data sources
last refreshed 41m ago
Found something off?
comments(0)
5-min edit window · permanent after that